Volume | 2,932,028 |
|
|||||
News | (1) | ||||||
Day High | 12.14 | Low High |
|||||
Day Low | 11.68 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Iovance Biotherapeutics Inc | IOVA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.92 | 11.68 | 12.14 | 11.71 | 11.86 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
22,727 | 2,932,028 | $ 11.86 | $ 34,769,187 | - | 3.21 - 18.33 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:42:33 | 2 | $ 11.69 | USD |
Iovance Biotherapeutics (IOVA) Options Flow Summary
Iovance Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.27B | 279.31M | - | 1.19M | -444.04M | -1.59 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Iovance Biotherapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IOVA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.96 | 12.14 | 11.01 | 11.59 | 3,677,789 | -0.25 | -2.09% |
1 Month | 14.20 | 15.18 | 11.01 | 12.90 | 4,463,363 | -2.49 | -17.54% |
3 Months | 7.78 | 18.33 | 7.60 | 13.84 | 9,273,346 | 3.93 | 50.51% |
6 Months | 3.51 | 18.33 | 3.47 | 10.39 | 8,354,315 | 8.20 | 233.62% |
1 Year | 5.79 | 18.33 | 3.21 | 8.80 | 7,176,143 | 5.92 | 102.25% |
3 Years | 31.73 | 33.55 | 3.21 | 10.67 | 4,459,154 | -20.02 | -63.09% |
5 Years | 11.01 | 54.2081 | 3.21 | 14.33 | 3,309,520 | 0.70 | 6.36% |
Iovance Biotherapeutics Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. |